SOHM Inc. Stock Analysis SHMN

SOHM, Inc. engages in the manufacture and marketing of generic drugs. The company is headquartered in Chino Hills, California. The company went IPO on 2006-10-11. The firm is focused on developing, manufacturing and distributing generic, branded generic, private label pharmaceuticals, cosmeceuticals and nutraceutical products. The Company’s products include Omega-3 with EPA, DHA & Vitamin D3, I-Prolec, Various Gummies, Levetiracetam, Hydroquinone USP, 4%, Sodium Sulfacetamide 10% Sulfur 2%, Sodium Sulfacetamide 9.8% Sulfur 4.8%, Sodium Sulfacetamide 10% Sulfur 5%, Nail Renovar, and Fohm by SOHM. The Company’s generic pharmaceuticals are exported globally with a focus on distribution in markets in Africa, Latin America, and Southeast Asia. The company has also acquired the intellectual property portfolio entitled Cas 9 retroviral integrase and Cas 9 recombinase systems for targeted incorporation of a DNA sequence into a genome of a cell or organism.